Remission of intestinal Behçet's disease treated with anti-tumor necrosis factor alpha monoclonal antibody (Infliximab)

Korean J Intern Med. 2007 Mar;22(1):24-7. doi: 10.3904/kjim.2007.22.1.24.

Abstract

Behçet's disease (BD) is a chronic relapsing multisystem disease characterized by oral ulceration, genital ulceration and ocular lesions. Gastrointestinal involvement is rare, often difficult to treat and associated with a high mortality rate. We treated a 47-year-old Korean man with BD who had a recurrent intestinal ulcer with tumor necrosis factor alpha antibody (infliximab); he initially underwent right hemicolectomy due to uncontrolled intestinal bleeding. For patients with intestinal BD who fail to respond to conventional treatment, infliximab may be a safe and effective new therapeutic option.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Behcet Syndrome / drug therapy*
  • Behcet Syndrome / physiopathology
  • Behcet Syndrome / surgery
  • Colectomy
  • Disease Progression
  • Gastrointestinal Agents / therapeutic use*
  • Gastrointestinal Diseases / drug therapy*
  • Gastrointestinal Diseases / etiology
  • Gastrointestinal Diseases / surgery
  • Humans
  • Infliximab
  • Male
  • Middle Aged
  • Remission Induction
  • Treatment Outcome*
  • Tumor Necrosis Factor-alpha / therapeutic use*

Substances

  • Antibodies, Monoclonal
  • Gastrointestinal Agents
  • Tumor Necrosis Factor-alpha
  • Infliximab